Latest news with #ChiragPatel
Yahoo
29-05-2025
- Business
- Yahoo
Amneal to Participate at Upcoming Investor Conferences in June
BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at with replays available following both events. About AmnealAmneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit and follow us on LinkedIn. Investor ContactAnthony DiMeoVP, Investor in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Hindustan Times
26-05-2025
- Entertainment
- Hindustan Times
HT City Delhi Junction: Catch It Live on 26 May 2025
What: Chirag Patel: In Pursuit of Parallels Where: Akar Prakar, D-43, First Floor, Defence Colony When: May 26 to June 21 Timing: 11am to 7pm Entry: Free Nearest Metro Station: Lajpat Nagar (Violet Line) What: Gharwali / Dil Ki Duniya Where: Blank Canvas, LTG Auditorium, Copernicus Marg, Mandi House When: May 26 Timing: 7pm Entry: Nearest Metro Station: Mandi House (Blue & Violet Lines) What: Bollywood Rhapsody Where: Klub Hermis (Ground Floor), Corporate Park, Lemon Tree Hotel, Sector 60, Gurugram When: May 26 Timing: 10pm Entry: Nearest Metro Station: Sector 55-56 (Rapid Metro) What: Noida Comedy Carnival Where: Upper Deck Comedy Club, Commercial Complex, Amarpali Silicon City, Sector 76, Noida When: May 26 Timing: 9pm Entry: Nearest Metro Station: Noida Sector 76 (Aqua Line)
Yahoo
16-05-2025
- Business
- Yahoo
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market's revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company's full-year revenue guidance of $3.05 billion at the midpoint came in 0.8% above analysts' estimates. Its non-GAAP profit of $0.21 per share was 43.2% above analysts' consensus estimates. Is now the time to buy AMRX? Find out in our full research report (it's free). Revenue: $695.4 million vs analyst estimates of $720.2 million (5.5% year-on-year growth, 3.4% miss) Adjusted EPS: $0.21 vs analyst estimates of $0.15 (43.2% beat) Adjusted EBITDA: $170 million vs analyst estimates of $161.7 million (24.4% margin, 5.1% beat) The company reconfirmed its revenue guidance for the full year of $3.05 billion at the midpoint Management reiterated its full-year Adjusted EPS guidance of $0.68 at the midpoint EBITDA guidance for the full year is $662.5 million at the midpoint, in line with analyst expectations Operating Margin: 14.4%, up from -1.6% in the same quarter last year Free Cash Flow was -$5.75 million compared to -$13.61 million in the same quarter last year Market Capitalization: $2.35 billion Amneal's first quarter was shaped by steady revenue growth across its core generics and branded specialty segments, with management crediting robust uptake of the Parkinson's drug CREXONT and expansion in injectables for the period's performance. The company continued to benefit from a diverse portfolio, new product launches, and a growing U.S. manufacturing footprint, while leadership cited operational efficiency initiatives and favorable product mix as factors behind the improvement in margins. Co-CEO Chirag Patel highlighted, 'We are embarking on our next phase of growth with momentum and confidence in our ability to deliver on our goals in 2025 and beyond.' Looking ahead, Amneal's management remains focused on execution across multiple growth drivers, including the scaling of its biosimilars business and the anticipated launch of additional specialty products. The company reaffirmed its full-year guidance, pointing to upcoming milestones in its injectable and biosimilar portfolios, the expansion of GLP-1 manufacturing capabilities, and further market access for CREXONT. Management stated that ongoing investments in digitization and automation support its long-term strategy of becoming a leading supplier of affordable medicines. Amneal's leadership attributed the quarter's outcome to portfolio breadth, successful new launches, and efficiency gains. Revenue missed Wall Street's expectations, but adjusted profit and margins exceeded consensus due to product mix and cost controls. CREXONT launch momentum: CREXONT, Amneal's branded Parkinson's medication, continued to exceed early expectations, with rapid market share gains and expanded insurance coverage from 30% to 60% of U.S. covered lives in six months. Management cited strong patient and provider feedback and expects CREXONT to reach peak sales between $300 million and $500 million. Injectables and new launches: The affordable medicines segment grew through a mix of complex generic and injectable product launches. The company introduced BORUZU, its fourth 505(b)(2) injectable in a year, highlighting a strategic emphasis on hospital-ready formulations that improve efficiency and reimbursement for providers. Biosimilars as a growth vector: Amneal's first three biosimilars generated $125 million in revenue in the last year. Five additional biosimilar regulatory filings are planned for this year, with a goal of vertical integration to capture more value and address a market where many biologic drugs are losing exclusivity. U.S. manufacturing as a differentiator: Leadership underscored Amneal's large U.S. manufacturing footprint, producing two-thirds of its medicines domestically. This provides supply chain resilience and a potential advantage if tariffs on imported pharmaceuticals increase. GLP-1 partnership and facility buildout: The partnership with Metsera positions Amneal as a supplier and commercial partner for next-generation weight loss (GLP-1) therapies. Construction of new peptide and oral fill-finish facilities is underway, aiming to support future supply and contract manufacturing opportunities. Management's outlook for the coming quarters is anchored in the expansion of its specialty and biosimilar portfolios, operational leverage, and continued investment in manufacturing capacity, with a focus on mitigating external risks such as tariffs. Specialty and biosimilars expansion: Growth is expected from additional launches in the specialty segment—including the DHE autoinjector for migraines—and the scaling of biosimilar offerings, which management believes will drive both revenue and margin improvement. Operational efficiency initiatives: Investments in automation, digitization, and supply chain optimization are expected to enhance margins and support cost containment, even as the company ramps up new product introductions. Tariff and regulatory risk management: The company's U.S. manufacturing base and proactive inventory and sourcing strategies are intended to limit the impact of potential tariffs or regulatory delays, though management noted that economic viability and customer acceptance of any cost increases remain important variables. David Amsellem (Piper Sandler): Asked for details on biosimilar revenue contribution and vertical integration timing; leadership confirmed a $150–$160 million target for biosimilars this year and expects vertical integration options to be finalized by early next year. David Amsellem (Piper Sandler): Inquired about the focus between complex and shortage-driven injectables; management stated they are prioritizing both equally, with ongoing launches in each area and infrastructure to support growth. Les Sulewski (Truist Securities): Queried about AvKARE's exposure to federal cuts; management responded federal cuts do not apply to pharmaceuticals and sees ongoing volume growth in government channels. Les Sulewski (Truist Securities): Asked about FDA approval timelines and CREXONT's ex-U.S. expansion; management reported no FDA delays and outlined ongoing partnerships for CREXONT in Europe, Latin America, and Asia. Chris Schott (JPMorgan): Requested insight on leverage of U.S. manufacturing in the event of tariffs; management highlighted available capacity and willingness to increase domestic production if economically justified, with discussions ongoing with major customers about sharing potential cost increases. In the quarters ahead, the StockStory team will be monitoring (1) the commercial uptake and payer coverage expansion of CREXONT and upcoming specialty launches, (2) progress on biosimilar regulatory filings and the pace of vertical integration, and (3) operational milestones related to new manufacturing facility buildouts and the GLP-1 partnership with Metsera. Sustained margin improvement and execution on complex injectable launches will also be key indicators of strategic progress. Amneal currently trades at a forward P/E ratio of 10.7×. In the wake of earnings, is it a buy or sell? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Vertex Announces Strategic Investment in AI Tax Compliance Startup Kintsugi
KING OF PRUSSIA, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) ('Vertex' or the 'Company'), a global provider of indirect tax technology solutions, today announced it has completed a strategic investment in Kintsugi, a San Francisco-based, AI-native startup focused on automating sales tax compliance for small and mid-size businesses (SMBs). Terms of the agreement include a $15 million minority investment representing a 10 percent ownership interest, as well as IP sharing and a commercial arrangement. Additionally, Vertex will join the Kintsugi Board of Directors. The adoption of tax automation solutions is growing substantially as businesses face increasing compliance complexity associated with eCommerce and SaaS growth, cross-border trade and a patchwork of new tax regulations. Kintsugi automates the entire sales tax compliance lifecycle for small businesses, including tax calculations, filings, and compliance monitoring across multiple jurisdictions. Founded in 2023, Kintsugi has experienced rapid growth and expansion within the U.S., Canada and Europe. 'Kintsugi brings innovative AI-enabled capabilities to address the needs of the indirect tax market in new and creative ways,' stated Chirag Patel, Vertex Chief Strategy Officer. 'Through the IP sharing agreement, this investment will help accelerate our AI roadmap to deliver new innovations for our mid-market and enterprise customers globally.' Kintsugi's AI-driven platform seamlessly integrates with digital accounting and payments processing platforms to enable powerful automation, a seamless onboarding experience, and rapid time-to-value for SMB businesses. "We're thrilled to partner with Vertex, a company that shares our commitment to transforming tax technology," said Pujun Bhatnagar, CEO of Kintsugi. "This investment validates our approach to solving the indirect tax challenges facing small and mid-sized businesses today. With Vertex's support, we can accelerate our mission to make tax compliance painless and accessible for growing businesses." Together, Vertex and Kintsugi will continue to push the boundaries of AI-driven tax technology and next-level user experiences. Vertex's investment in Kintsugi is separate from the $10-12 million the company announced it would spend in AI technologies in 2025. Vertex plans to leverage Kintsugi's IP to advance these initiatives. Given the minority investment, Vertex will not consolidate the results of Kintsugi and the ownership will be accounted for at cost and reflected on the company's balance sheet. About Vertex Vertex, Inc. is a leading global provider of indirect tax solutions. The Company's mission is to deliver the most trusted tax technology enabling global businesses to transact, comply and grow with confidence. Vertex provides solutions that can be tailored to specific industries for major lines of indirect tax, including sales and consumer use, value added and payroll. Headquartered in North America, and with offices in South America and Europe, Vertex empowers the world's leading brands to simplify the complexity of continuous compliance. For more information, visit or follow us on X and LinkedIn. COPYRIGHT © 2025 VERTEX, INC. ALL RIGHTS RESERVED. THE INFORMATION CONTAINED HEREIN IS INTENDED FOR INFORMATION PURPOSES ONLY, MAY CHANGE AT ANY TIME IN THE FUTURE, AND IS NOT LEGAL OR TAX ADVICE. About Kintsugi Kintsugi provides an AI-powered tax automation platform that transforms complex tax management into a streamlined, automated process. By leveraging artificial intelligence and seamless integrations, Kintsugi reduces preparation time by 75% and compliance costs by 50% for e-commerce and SaaS businesses. The company offers transparent pricing, exceptional customer service, and advanced capabilities for multi-state and international tax compliance. Learn more at Vertex Company Contact: Joe CrivelliVP, Investor Relationsinvestors@ Rachel Litcofsky Manager, Public Relations mediainquiries@ Kintsugi Company Contact: Steve Moskovitz Head of MarketingSteve@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
